Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Rondy, Marc; Kissling, Esther; Emborg, Hanne-Dorthe; Gherasim, Alin Manuel; Pebody, Richard; Trebbien, Ramona; Pozo Sanchez, Francisco; Larrauri, Amparo; McMenamin, Jim; Valenciano, Marta; I-MOVE/I-MOVE+ group; Delgado-Sanz, Concepcion; Oliva Dominguez, Jesus Angel; Casas Flecha, Inmaculada

doi:10.2807/1560-7917.ES.2018.23.9.18-00086

Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/8992

Title

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Author(s)

Date issued

2018

Citation

Euro Surveill. 2018 Mar;23(9):18-00086.

Language

Inglés

Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

Subject

MESH